SWITCHING BETWEEN THE JAK1-SELECTIVE INHIBITOR-UPADACITINIB AND ADALIMUMAB FOLLOWING INITIAL NON-RESPONSE: CLINICAL AND FUNCTIONAL OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS Genovese, M. C., Fleischmann, R., Blanco, R., Hall, S., Thomson, G., van den Bosch, F., Zerbini, C., Enejosa, J., Li Yihan, Demasi, R., Song, I. BMJ PUBLISHING GROUP. 2019: 83–84

View details for DOI 10.1136/annrheumdis-2019-eular.2886

View details for Web of Science ID 000472207100243